GlassScriptPhysician profile
Robert B Boswell
NPI 1821182247
$1,044.62
in general payments reported to CMS, 2019-2025
22 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $13.55 · 2021: $51.50 · 2022: $57.24 · 2023: $127 · 2024: $97.15 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $340.36 | 2019 | |
| Pfizer INC. | $88.21 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $80.92 | 2023-2024 | |
| Philips North America LLC | $48.31 | 2019-2024 | (Ck7) Extended Holter |
| Impulse Dynamics (USA) INC. | $44.37 | 2022 | |
| Boston Scientific Corporation | $42.11 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $40.80 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $37.01 | 2019 | |
| Amgen INC. | $33.93 | 2019-2023 | Repatha |
| Livanova USA, INC. | $30.84 | 2021 | |
| Kestra Medical Technology Services, INC. | $28.85 | 2025 | Assure Wcd |
| Allergan, INC. | $28.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.49 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $24.95 | 2025 | |
| Abbott Laboratories | $21.53 | 2025 | Cardiomems |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.74 | 2019 | |
| Gilead Sciences, INC. | $20.66 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.61 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $16.00 | 2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.